Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Genmab plans to present full results at an upcoming medical meeting.

Researchers sought to determine whether zanubrutinib combined with rituximab and lenalidomide would improve remission rates in older adults with newly diagnosed DLBCL.

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...